gene editing
Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform
May 30, 2025Medical Communications, Research and Development Bill and Melinda Gates Foundation, Gene Weaver, Oncology, Pharmacy, Rare Diseases, funding, gene editing
UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance its programmable gene insertion technology …
Regeneron and Mammoth Biosciences announce CRISPR collaboration
April 26, 2024Research and Development Pharmacy, Regeneron, crispr, gene editing
Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene …
Researchers have tested CRISPR gene editing inside a person’s body for the first time
March 5, 2020Business Services Editas, crispr, gene editing
Allergan and Editas Medicine have treated their first patient in a clinical trial with CRISPR gene editing. This therapy is …
Genetically modified twins may have been altered in a way that improves memory and cognition
February 22, 2019Medical Communications CCR5, HIV, cognitive enhancement, crispr, gene editing
The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that …
Scientist who genetically modified babies faces punishment after acting illegally, Chinese authorities confirm
January 22, 2019Manufacturing and Production China, He Jiankui, crispr, ethics, gene editing
Chinese state media have confirmed that He Jiankui, the scientist who claimed to have genetically modified babies to prevent them …
Researchers eliminate mosquito population through CRISPR gene editing technology
September 27, 2018Research and Development crispr, gene editing, imperial college london, malaria, mosquitoes
Researchers at Imperial College London have been able to wipe out a population of mosquitoes through ‘gene drive’ technology. The …
CRISPR gene editing may frequently cause undetected genetic damage
July 17, 2018Manufacturing and Production DNA, crispr, gene editing, genetic damage
Scientists studying the gene editing technology CRISPR-Cas9 have discovered the technique appears to frequently cause genetic damage that may slip …
Gene editing carried out, distances ‘designer baby’ possibility
August 3, 2017Research and Development biotech, crispr, drugs, gene editing, pharma, pharmaceutical
The news broke last week that scientists in the US had carried out the first gene editing testing in the …
US scientists carry out first editing of human embryos
July 28, 2017Medical Communications, Research and Development biotech, crispr, drugs, gene editing, gene-editing, pharma, pharmaceutical
In what will be regarded as a watershed moment, scientists working at Oregon Health and Science University have used CRISPR …
US panel endorses human embryo gene editing, with caveats
February 15, 2017Research and Development crispr, gene editing
Gene editing in human embryos has been given the go-ahead by a panel of experts from the US National Academy …
Horizon and Fulcrum Therapeutics form CRISPR collaboration
September 6, 2016Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases
Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform …
Bayer’s CRISPR venture opens for business in biotech hub
August 23, 2016Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing
Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …
Federal panel to review proposal for first human CRISPR test
June 20, 2016Research and Development, Sales and Marketing crispr, gene editing, human testing, oncology
A US Federal safety board is set to review a proposal for the first human use of the gene editing …
Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics
Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
